Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Protein Effect||no effect|
|Gene Variant Descriptions||CBL dec exp indicates decreased expression of the Cbl protein. However, the mechanism causing the decreased expression is unspecified.|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CBL dec exp||pancreatic ductal carcinoma||predicted - sensitive||Erlotinib + Gemcitabine||Preclinical - Cell line xenograft||Emerging||In a preclinical study, addition of Tarceva (erlotinib) overcame Gemzar (gemcitabine)-resistance in pancreatic ductal carcinoma cell lines with reduced Cbl expression via shRNA, resulted in decreased viability in cell culture and reduced tumor growth in cell line xenograft models (PMID: 25348515).||25348515|
|Molecular Profile||Protein Effect||Treatment Approaches|
|CBL dec exp||no effect|